Relay Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Par Value | Capital | Income/(Loss) | Deficit | Equity | |
| Balances at December 31, 2020 | 89,906,835 | $90 | $1,167,367 | $64 | $(404,228) | $763,293 |
| Issuance of common stock upon acquisition of ZebiAI | 1,914,219 | 2 | 62,990 | — | — | 62,992 |
| Issuance of common stock through follow-on offering, net | 15,188,679 | 15 | 382,195 | — | — | 382,210 |
| Issuance of common stock through exercise of stock options | 996,536 | 1 | 4,738 | — | — | 4,739 |
| Issuance of common stock via employee stock purchase plan | 43,685 | 1 | 1,140 | — | — | 1,141 |
| Vesting of restricted common stock | 84,489 | — | 3 | — | — | 3 |
| Vesting of restricted stock units | 75,875 | — | — | — | — | — |
| Stock compensation expense | — | — | 48,454 | — | — | 48,454 |
| Unrealized loss on investments | — | — | — | (1,152) | — | (1,152) |
| Net loss | — | — | — | — | (363,872) | (363,872) |
| Balances at December 31, 2021 | 108,210,318 | $109 | $1,666,887 | $(1,088) | $(768,100) | $897,808 |
| Issuance of common stock upon milestone achievement | 301,939 | — | 6,203 | — | — | 6,203 |
| Issuance of common stock through follow-on offering, net | 11,320,755 | 11 | 284,733 | — | — | 284,744 |
| Issuance of common stock through exercise of stock options | 757,873 | 1 | 3,479 | — | — | 3,480 |
| Issuance of common stock via employee stock purchase plan | 123,019 | — | 1,686 | — | — | 1,686 |
| Vesting of restricted stock units | 398,330 | — | — | — | — | — |
| Stock compensation expense | — | — | 56,138 | — | — | 56,138 |
| Unrealized loss on investments | — | — | — | (9,332) | — | (9,332) |
| Net loss | — | — | — | — | (290,509) | (290,509) |
| Balance at December 31, 2022 | 121,112,234 | $121 | $2,019,126 | $(10,420) | $(1,058,609) | $950,218 |
| Issuance of common stock upon milestone achievement | 1,797,064 | 2 | 12,748 | — | — | 12,750 |
| Issuance of common stock via At-the-Market offerings, net | 3,026,072 | 3 | 30,278 | — | — | 30,281 |
| Issuance of common stock through exercise of stock options | 399,498 | 1 | 1,985 | — | — | 1,986 |
| Issuance of common stock via employee stock purchase plan | 244,125 | — | 2,486 | — | — | 2,486 |
| Vesting of restricted stock units | 883,416 | — | — | — | — | — |
| Stock compensation expense | — | — | 86,031 | — | — | 86,031 |
| Unrealized gain on investments | — | — | — | 10,224 | — | 10,224 |
| Net loss | — | — | — | — | (341,973) | (341,973) |
| Balances at December 31, 2023 | 127,462,409 | $127 | $2,152,654 | $(196) | $(1,400,582) | $752,003 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.